Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987919 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
A Phase 3 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,879
- Enrollment target
- 20
- Study locations
NCT03987919: Completed Phase 3 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
NCT03987919 is a Phase 3 study of Type 2 Diabetes that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,879 participants, below the 3,918-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03987919, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,879 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Primary Outcome
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
Study Locations (20)
California
- National Research Institute - Huntington Park - Huntington Park
- Catalina Research Institute, LLC - Montclair
- Valley Clinical Trials, Inc. - Northridge
- National Research Institute - Huntington Park - Panorama City
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
- Artemis Institute for Clinical Research - San Marcos
- University Clinical Investigators, Inc. - Tustin
Florida
- Clinical Research of South Florida - Coral Gables
- East Coast Institute for Research at The Jones Center - Lake City
- South Florida Clinical Research Institute - Margate
- Suncoast Research Group - Miami
- New Horizon Research Center - Miami
- Oviedo Medical Research - Oviedo
- South Broward Research - Pembroke Pines
Alabama
- Cahaba Research - Birmingham
- Syed Research Consultants Llc - Sheffield
Georgia
- United Osteoporosis Center - Gainesville
- Sky Clinical Research Network - Union City
Connecticut
- CMR of Greater New Haven - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,879 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2021-02-15 |
| Phase | Phase 3 |
What the finished NCT03987919 record still lists
NCT03987919 is an interventional study that assigns participants to a tested intervention. Its 1,879 participants enrollment target places it among the larger protocols in the corpus, below the 3,918-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT03987919 names 20 study sites across 5 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03987919 about?
NCT03987919 is a clinical study titled "A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes". The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
What is the current status of trial NCT03987919?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,879 participants. The study started on 2019-07-30. Estimated completion is 2021-02-15.
What conditions does trial NCT03987919 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT03987919?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT03987919?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03987919 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03987919's enrollment target sits among peer trials
1,879 15th of 327 higher than 313 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06438640 · 1,881 participants · NA
Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT06891898 · 1,875 participants
The iLet Experience Study
- NCT07356089 · 1,875 participants
Twiist Postmarket Surveillance Study for Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI